Skip to main content
. 2015 Oct 12;172(1):111–121. doi: 10.1111/bjh.13803

Figure 1.

Figure 1

Kaplan–Meier curves for progression‐free survival (A) in the entire study population and (B) according to 18Ffluorodeoxyglucose‐positron emission tomography (PET) status before FEAM regimen (fotemustine, etoposide, cytarabine, melphalan).